HCPLive 5 Stories in Under 5: Week of 05/18 Podcast Por arte de portada

HCPLive 5 Stories in Under 5: Week of 05/18

HCPLive 5 Stories in Under 5: Week of 05/18

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

 Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 Healthcare Headlines for May 12-18, 2025.

FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis

The FDA approved once-daily roflumilast (Zoryve) foam 0.3% for treating plaque psoriasis on the scalp and body in patients aged 12 and older. This marks the fifth overall indication for roflumilast, adding to its existing approvals in psoriasis and atopic dermatitis.

FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine

The FDA issued a warning about severe pruritus that can occur after stopping long-term cetirizine or levocetirizine use. Manufacturers will be required to add a label warning noting that symptoms may improve if the medications are restarted.

FDA Approves Susvimo for Treatment of Diabetic Retinopathy

The FDA approved Genentech’s Susvimo, a ranibizumab delivery system, as the first continuous refillable treatment for diabetic retinopathy. Susvimo offers sustained vision maintenance with refills needed only once every nine months.

Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study

The Essence study showed olezarsen significantly reduced triglyceride levels in patients with moderate hypertriglyceridemia at ASCVD risk. Monthly doses achieved about 60% reductions, with most patients reaching normal triglyceride levels after six months.

Ruxoprubart Shows Efficacy for PNH in Interim Phase 2 Trial Results

Interim Phase 2 results showed ruxoprubart met all primary efficacy endpoints in adults with paroxysmal nocturnal hemoglobinuria. The therapy led to transfusion avoidance, improved hemoglobin, reduced LDH, and increased PNH clone size at 12 weeks.
Todavía no hay opiniones